5 results about "Tumor-Specific Antibody" patented technology

This invention relates to the use of small molecule compounds that allosterically inhibit ALC1 (CHD1L), particularly two classes of ALC1 (CHD1L) allosteric inhibitors of formulas (I) and (II). When combined with inhibitors of several classes of cancer drugs, namely topoisomerase I, topoisomerase II, ATM, ATR, Wee1, BRD, and MEK, or when combined with mitomycin C, paclitaxel, ionizing radiation, or antibody-drug conjugates having tumor-specific antibodies conjugated to TOP1 inhibitors, the small molecule compounds and the allosteric inhibitors exhibit enhancing, preferably additive, effects in the treatment of proliferative diseases. Furthermore, this invention relates to the ALC1 inhibitor of formula (II), which, when combined with PARP inhibitors (poly(ADP-ribose)-polymerase inhibitors (PARPi)), exhibit synergistic effects in the treatment of pancreatic cancer or fallopian tube cancer. By synergizing with the functions of the aforementioned cancer drugs, the ALC1 inhibitors, particularly those of formulas (I) and (II) that enhance the cancer cell killing properties of the aforementioned cancer drugs, are particularly capable of achieving treatments in which any of the aforementioned inhibitors have already been used as part of standard care.

Provided are compositions and methods for improving tumor penetrability of anti-tumor antibodies or conjugates thereof. The method comprises administering to an individual in need of treatment an anti-idiotypic antibody in addition to the anti-tumor antibody or conjugate. Examples are provided for anti-HER2 antibodies and anti-idiotypic antibodies that are directed to the anti-HER2 antibodies.

Methods, devices and systems are provided to analyze the immunologic response of patients at various times before, during and / or after immunomodulating therapy, particularly treatment with specialized pulsed electric field energy. In some embodiments, such methods, devices and systems include a laboratory developed test that utilizes a patient tumor biopsy sample and a series of blood draws to determine whether the locoregional therapy (with or without additional systemic therapies, or systemic therapies-alone) was sufficient to facilitate an increase in tumor-specific antibody production. In some embodiments, the focus is on evaluation of baseline antibody levels, prior to any treatment, and changes in levels of antibodies to given antigens, especially in response to a given therapy treatment. In such embodiments, this antibody testing is performed prior to treatment. The treatment, such as delivery of specialized PEF energy to a target tissue, is then performed and antibody levels are checked at one or more later timepoints to detect changes in the presence of antibodies and therefore response to therapy.

The present application relates to a series of 2'-deoxy-2',2'-difluoro cytidine (2',2'-difluoro 2'-deoxycytidine, dFdC, gemcitabine) Protide and antibody specific to tumor antigen form conjugates and its preparation method and application in the field of treatment. Further, the present application provides a series of antibody-linker-2'-deoxy-2',2'-difluoro cytidine Protide conjugate to form antibody drug conjugate (ADC). The structural features are mainly in the 5'-phosphate phenylamide amino acid ester corresponding group in the structure of 2'-deoxy-2',2'-difluoro cytidine and the linker for linkage, and then coupled with the corresponding tumor specific antibody to form ADC. These ADCs target antigens on tumor cells, endocytose into tumor cells, release the drug 2'-deoxy-2',2'-difluoro cytidine monophosphate, kill tumor cells, and cause tumor cell apoptosis.

This invention relates to a jet microneedle delivery device capable of achieving controllable initial diffusion and precise targeted drug delivery, compositions for local tumor injection, drug-device combination products, and their use in the preparation of drugs for local tumor injection. The jet microneedle delivery device uses a conventional needle-free jet injection power source, combined with one or more microneedles to achieve diffusion and precise delivery. The composition includes a boron compound drug component, an immune adjuvant, and a drug carrier. Through a specially designed jet microneedle delivery device, boron compound radiotherapy drugs can be delivered locally to the tumor, avoiding the problems of traditional intravenous administration where drugs struggle to reach the tumor interior and surface, and where systemic toxicity or overdose radioactivity limits the maximum drug dose and therapeutic effect. The high-concentration local delivery of the composition not only improves the local therapeutic effect on the tumor but also effectively generates tumor-specific antibodies through neoantigens produced during treatment, assisted by the immune adjuvant.